Misplaced Pages

This is an old revision of this page, as edited by Schlenk (talk | contribs) at 20:40, 19 April 2016 (Reverted manually to Monkbot's version). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Satraplatin

Clinical data
Other names	BMY 45594 BMS 182751 (OC-6-43)-bis(acetato)amminedichlorocyclohexylamine platinum(IV)
Routes of administration	Oral
ATC code	L01XA04 (WHO)
Identifiers
IUPAC name (OC-6-43)-bis(acetato)amminedichloro(cyclohexylamine)platinum
CAS Number	129580-63-8
PubChem CID	123974
UNII	8D7B37T28G
ChEBI	CHEBI:85609
CompTox Dashboard (EPA)	DTXSID00926438
Chemical and physical data
Formula	C10H22Cl2N2O4Pt
Molar mass	500.277 g/mol g·mol
(verify)

Satraplatin (INN, codenamed JM216) is a platinum-based antineoplastic agent that is under investigation as one treatment of patients with advanced prostate cancer who have failed previous chemotherapy. It has not yet received approval from the U.S. Food and Drug Administration. First mentioned in the medical literature in 1993, satraplatin is the first orally active platinum-based chemotherapeutic drug; other available platinum analogues—cisplatin, carboplatin, and oxaliplatin—must be given intravenously.

It is made available in the United States jointly by Spectrum Pharmaceuticals and GPC Biotech under the name SPERA (SatraPlatin Expanded Rapid Access).

The drug has also been used in the treatment of lung and ovarian cancers. The proposed mode of action is that the compound binds to the DNA of cancer cells rendering them incapable of dividing.

References

1. Wheate, Nial J.; Walker, Shonagh; Craig, Gemma E.; Oun, Rabbab (2010). "The status of platinum anticancer drugs in the clinic and in clinical trials". Dalton Transactions. 39 (35): 8113–27. doi:10.1039/C0DT00292E. PMID 20593091.
2. Kelland LR, Abel G, McKeage MJ, et al. (1993). "Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug" (PDF). Cancer Res. 53 (11): 2581–6. PMID 8388318.
3. Choy H, Park C, Yao M (2008). "Current status and future prospects for satraplatin, an oral platinum analogue". Clin Cancer Res. 14 (6): 1633–8. doi:10.1158/1078-0432.CCR-07-2176. PMID 18347164.{{cite journal}}: CS1 maint: multiple names: authors list (link)
4. Satraplatin — Spectrum Pharmaceuticals

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Coordination compounds
• Platinum compounds
• Acetates
• Platinum-based antineoplastic agents
• Antineoplastic and immunomodulating drug stubs